drugset / Trial / NCT04251182
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects
Phase 2
Completed
250 enrolled
T3D Therapeutics, Inc.
Alzheimer's Association · collabClinilabs, Inc. · collabNational Institute on Aging (NIA) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects with Mild-to-Moderate Alzheimer's Disease.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2023-01-20
- Completion
- 2023-02-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DB959 | Small molecule | 15 mg | Oral |
| Subject | DB959 | Small molecule | 30 mg | Oral |
| Subject | DB959 | Small molecule | 45 mg | Oral |